CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Xiaoyi Hu; Asiri Ediriwickrema; Atif Saleem; Brent Tan; Naveen Pemmaraju; Gabriel N. Mannis

doi:10.1016/j.leukres.2024.107479

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Xiaoyi Hu, Asiri Ediriwickrema, Atif Saleem, Brent Tan, Naveen Pemmaraju, Gabriel N. Mannis

Leukemia

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Article number	107479
Journal	Leukemia Research
Volume	139
DOIs	https://doi.org/10.1016/j.leukres.2024.107479
State	Published - Apr 2024

Keywords

BPDCN
CD123
Daratumumab
Tagraxofusp
Venetoclax

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2024.107479

Cite this

@article{2d5f7161f34b449686d947d95e185e5a,

title = "CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123",

keywords = "BPDCN, CD123, Daratumumab, Tagraxofusp, Venetoclax",

author = "Xiaoyi Hu and Asiri Ediriwickrema and Atif Saleem and Brent Tan and Naveen Pemmaraju and Mannis, {Gabriel N.}",

year = "2024",

month = apr,

doi = "10.1016/j.leukres.2024.107479",

language = "English (US)",

volume = "139",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

AU - Hu, Xiaoyi

AU - Ediriwickrema, Asiri

AU - Saleem, Atif

AU - Tan, Brent

AU - Pemmaraju, Naveen

AU - Mannis, Gabriel N.

PY - 2024/4

Y1 - 2024/4

KW - BPDCN

KW - CD123

KW - Daratumumab

KW - Tagraxofusp

KW - Venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85187723294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85187723294&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2024.107479

DO - 10.1016/j.leukres.2024.107479

M3 - Letter

C2 - 38492495

AN - SCOPUS:85187723294

SN - 0145-2126

VL - 139

JO - Leukemia Research

JF - Leukemia Research

M1 - 107479

ER -

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this